News
Rheums Speak: Future of Rheumatoid Arthritis
The third survey in this series addressed clinician views on future trends (AI), future therapies and lessons learned.
Uncertainty with immunosuppressive for idiopathic inflammatory myopathies
A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies (IIM). Overall there has been little progress since the previous Cochrane review (2012) that found little or no evidence to guide treatment.TNF Inhibitors in Takayasu's Arteritis
A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis.
Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer
Teaching You How to Think⦠(8.15.2025)
Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogren's trial, to PT or not to PT, and aphorisms to live by.
Glossary for Giant Cell Arteritis
Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.
The Patient Journey with Rheumatic Disease
Biologic Switching in Psoriasis
A systematic review and meta-analysis found that biologic switching was effective in a significant number of psoriasis patients; but there may be a price to pay.